| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Molecular Biology, DCBDC [T. I. P., D. J. F., I. P.], and Pediatric Branch, Division of Cancer Treatment [L. J. H.], National Cancer Institute, NIH, Bethesda, Maryland 20892
A chimeric toxin in which the cell binding domain of Pseudomonas exotoxin was replaced with mature human insulin-like growth factor I (IGF-I) was produced in Escherichia coli. This protein, IGF-I-PE40, was cytotoxic to human cell lines derived from a variety of tumor types, with a breast carcinoma line (MCF-7) and two hepatoma lines (HEP3B and HEPG2) showing the highest sensitivity to the toxin. The specificity of IGF-I-PE40 cytotoxicity was confirmed through competition with excess IGF-I and through blockage of toxin binding using an antibody specific to the type I IGF receptor. A potential interaction between the toxin and soluble IGF-binding proteins was also demonstrated. IGF-I-PE40 may be useful in the selective elimination of cells bearing the type I IGF receptor.
1 To whom requests for reprints should be addressed.
Received 8/ 8/90. Accepted 10/ 9/90.
This article has been cited by other articles:
![]() |
M. Kawakami, K. Kawakami, V. A. Stepensky, R. A. Maki, H. Robin, W. Muller, S. R. Husain, and R. K. Puri Interleukin 4 Receptor on Human Lung Cancer: A Molecular Target for Cytotoxin Therapy Clin. Cancer Res., November 1, 2002; 8(11): 3503 - 3511. [Abstract] [Full Text] [PDF] |
||||
![]() |
I Pastan and D FitzGerald Recombinant toxins for cancer treatment Science, November 22, 1991; 254(5035): 1173 - 1177. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |